首页> 外文OA文献 >Purine homo-N-nucleoside+coumarin hybrids as pleiotropic agents for the potential treatment of Alzheimer's disease
【2h】

Purine homo-N-nucleoside+coumarin hybrids as pleiotropic agents for the potential treatment of Alzheimer's disease

机译:嘌呤同型N-核苷+香豆素杂种作为多效药物,可潜在治疗阿尔茨海默氏病

摘要

Aim: Due to the complex nature of Alzheimer's disease, there is a renewed search for pleiotropic agents. Results: Purine+coumarin hybrids have been synthesized and tested for the potential treatment of Alzheimer's disease. Hybrids 6, 4a-b, 14c and 14e inhibit significantly soybean lipoxygenase, whereas derivatives 14b, c and 20a present antioxidative/lipoxygenase inhibition activities. Cholinesterase (ChE) and monoamino oxidase (MAO) inhibition studies have been carried out. Hybrid 20a is the most potent ChE inhibitor, in the low micromolar range, and selective for hBuChE (IC50 = 4.65 ± 0.23 μM), whereas hybrid 14a is the most potent MAOI, in the low micromolar range, and selective for MAO-B (IC50 = 6.8 ± 0.6 μM). Conclusion: The preliminary experimental results point to two selective multitarget lead compounds 20a and 4b.
机译:目的:由于阿尔茨海默氏病的复杂性,人们重新寻找多效性药物。结果:嘌呤+香豆素杂种已合成并经过测试可用于治疗阿尔茨海默氏病。杂种6、4a-b,14c和14e显着抑制大豆脂氧合酶,而衍生物14b,c和20a具有抗氧化/脂氧合酶抑制活性。已经进行了胆碱酯酶(ChE)和单氨基氧化酶(MAO)的抑制研究。杂合体20a在低微摩尔范围内是最有效的ChE抑制剂,对hBuChE具有选择性(IC50 = 4.65±0.23μM),而杂合体14a在低微摩尔范围内是最有效的MAOI,对MAO-B具有选择性( IC50 = 6.8±0.6μM)。结论:初步的实验结果指出了两种选择性的多靶点先导化合物20a和4b。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号